Physical Methods to Characterize Pharmaceutical Proteins

  • James N. Herron
  • Wim Jiskoot
  • Daan J. A. Crommelin

Part of the Pharmaceutical Biotechnology book series (PBIO, volume 7)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Wim Jiskoot, Vladimir Hlady, John J. Naleway, James N. Herron
    Pages 1-63
  3. Peter Roepstorff
    Pages 145-177
  4. David G. Vander Velde, James Matsuura, Mark C. Manning
    Pages 179-218
  5. Kenneth P. Murphy, Ernesto Freire
    Pages 219-241
  6. Joost J. M. Holthuis, Reinoud J. Driebergen
    Pages 243-299
  7. Tom A. A. M. van de Goor
    Pages 301-327
  8. Back Matter
    Pages 351-362

About this book


Proteins are still gaining importance in the pharmaceutical world, where they are used to improve our arsenal of therapeutic drugs and vaccines and as diagnostic tools. Proteins are different from "traditional" low-molecular-weight drugs. As a group, they exhibit a number of biopharmaceutical and formulation problems. These problems have drawn considerable interest from both industrial and aca­ demic environments, forcing pharmaceutical scientists to explore a domain previ­ ously examined only by peptide and protein chemists. Biopharmaceutical aspects of proteins, e.g., low oral bioavailability, have been extensively investigated. Although all possible conventional routes of ad­ ministration have been examined for proteins, no real, generally applicable alter­ native to parenteral administration in order to achieve systemic effects has yet been discovered. Several of these biopharmaceutical options have been discussed in Volume 4 of this series, Biological Barriers to Protein Delivery. Proteins are composed of many amino acids, several of which are notorious for their chemical instability. Rational design of formulations that optimize the native structure and/or bioactivity of a protein is therefore of great importance when long shelf life is required, as it is for pharmaceutical products. This issue has also been examined in two prior volumes of this series: Volume 2: Stability of Protein Pharmaceuticals (Part A) and Volume 5: Stability and Characterization of Protein and Peptide Drugs.


fluorescence infrared spectroscopy magnetic resonance proteins spectroscopy

Editors and affiliations

  • James N. Herron
    • 1
  • Wim Jiskoot
    • 2
  • Daan J. A. Crommelin
    • 3
  1. 1.University of UtahSalt Lake CityUSA
  2. 2.National Institute of Public Health and Environmental ProtectionBilthovenThe Netherlands
  3. 3.Groningen-Utrecht Institute for Drug ExplorationUtrecht University, and Utrecht Institute for Pharmaceutical SciencesUtrechtThe Netherlands

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1995
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4899-1081-3
  • Online ISBN 978-1-4899-1079-0
  • Series Print ISSN 1078-0467
  • Buy this book on publisher's site